Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: A randomised phase III trial of Turkish Oncology Group

British Journal of Cancer

Volumn 92, Issue 4, 2005, Pages 639-644

  Icli, F ^a   Akbulut, H ^a   Uner, A ^b   Yalcin, B ^a   Baltali, E ^c   Altinbas, M ^d   Coskun S ^d   Komurcu, S ^e   Erkisi, M ^f   Demirkazik, A ^a   Senler, F C ^a   Sencan, O ^a   Buyukcelik A ^a   Boruban, C ^a   Onur, H ^a   Zengin, N ^a   Sak, S D ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

^d ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^e GULHANE SCHOOL OF MEDICINE   (Turkey)

^f CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Advanced breast cancer; Anthracycline; Cisplatin; Etoposide; Paclitaxel

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; PACLITAXEL; VINBLASTINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER GROWTH; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEBRILE NEUTROPENIA; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; BREAST TUMOR; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; SURVIVAL; TURKEY (REPUBLIC);

ADMINISTRATION, ORAL; ADULT; AGED; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TURKEY;

EID: 20144379656     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602388     Document Type: Article

References (29)

1. Abrams JS, Vena DA, Baltz J, Adams J, Montello M, Christian M, Onetto N, Desmond-Hellmann S, Canetta R, Friedman MA (1995) Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute referral center. J Clin Oncol 13: 2056-2065
2. Athanassiades P, Bacoyiannes H, Kontoyiannes D (1986) Etoposide and cisdichlorodiammine platinum in advanced breast carcinoma resistant to previous chemotherapy. Chemioterapia 5: 125-127
3. Atienza DM, Vogel CL, Trock B, Swain SM (1995) Phase II study of oral etoposide for patients with advanced breast cancer. Cancer 12: 2485-2490
4. Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Fargeot P, Assadourian S (2002) Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87: 1210-1215
5. Bontenbal M, Planting AS, Verweij J, de Wit R, Kruit WH, Stoter G, Klijn JG (1995) Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer. Breast Cancer Res Treat 34: 185-189
6. Burchenal JH, Kalaher K, Dew K, Lokys L (1979) Rationale for development of platinum analogs. Cancer Treat Rep 63: 1493-1498
7. Calvert AH, Lind MJ, Millward MM, Cantwell BM, Gumbrell L, Proctor M, Simmons D, Chapman F, Robinson A, Charlton C (1993) Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results. Cancer Treat Rev 19(Suppl C): 27-33
8. Ceci G, Bisagni G, Cocconi G, Rodino C, Belsanti V, Bertusi M, Buzzi F, Bacchi M (1995) Cisplatin and VP-16 in metastatic breast carcinoma as third line chemotherapy: a randomised study comparing low vs high dose of cisplatin. Tumori 81: 241-244
9. Cocconi G, Bisagni G, Bacchi M, Boni C, Bartolucci R, Ceci G, Colozza MA, De Lisi V, Lottici R, Mosconi AM (1991) Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 9: 664-669
10. Cocconi G, Tonato M, Dicostanzo F, Bisagni G, Belsanti V, Buzzi F, Ceci G (1986) Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Research (GOIRC). Eur J Clin Oncol 22: 761-764
11. Cox EB, Burton GV, Olsen GA, Vugrin D (1989) Cisplatin and etoposide: an effective treatment for refractory breast carcinoma. Am J Clin Oncol 12: 53-56
12. Fried G, Stein ME, Haim N (2000) Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: a phase II study. Med Ped Oncol 34: 10-13
13. Giaccone G, Donadio M, Ferrati P, Calciati A (1988) Cisplatin and etoposide in chemotherapy-refractory advanced breast cancer. Tumori 74: 191-193
14. Icli F, Akbulut H, Dinçol D, Onur H, Demirkazik A, Cam R, Cay F, Demirci S, Uner A, Erekul S (2001) A randomized trial of four cycles of adjuvant AC (adriamycin+cyclophosphamide) ± two cycles of EP (etoposide+ cisplatin) in node positive patients with breast cancer. Ann Oncol 12: 1011-1013
15. Icli F, Demirkazik A (1998) Cisplatin and oral etoposide (PEO) in heavily pretreated patients with advanced breast cancer. Proc ASCO 17: 560 (abstr)
16. Icli F, Günel N, Dinçol D, Gunel N, Karaoguz H, Demirkazik A (1992) Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer. J Surg Oncol 50: 251-253
17. Krook JE, Loprinzi CL, Schaid DJ, Kardinal CG, Mailliard JA, Pfeifle DM, Ellison NM, Reuter NF, Nelimark RA (1990) Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer. A colloborative North Central Cancer Treatment Group Mayo Clinic phase II study. Cancer 65: 418-421
18. Mabel JA, Little AD (1981) Therapeutic synergism in murine tumors for combination of cisdiammine-dichloroplatinum with VP16-213 or BCNU. Proc AACR-ASCO 22: 357
19. Martin M, Lluch A, Casado A, Santabarbara P, Adrover E, Valverde JJ, Lopez-Martin JA, Rodriguez-Lescure A, Azagra P, Garcia-Conde J (1994) Clinical activity of chronic oral etoposide in previously treatment metastatic breast cancer. J Clin Oncol 12: 986-991
20. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858-1867
21. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M (1999) Prospective randomized trial of docetaxel vs mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413-1424
22. Palombo H, Estape J, Vinolas N, Grau JJ, Mane JM, Daniels M, Mellado B (1994) Chronic oral etoposide in advanced breast cancer. Cancer Chemother Pharmacol 33: 527-529
23. Ravdin P, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba W, Olsen S, Meyers ML, Jones S (2003) Phase III comparison of docetaxel and paclitaxel in patients with metastatic breast cancer. Eur J Cancer 1(Suppl 5): S201
24. Remick SC, Chmura M, Drior CT, Sporn J, Healey B, Hilstro J, DeConti RC, Horton J, Ruckdeschel JC, Harper GR (1996) Concurrent 72 h continuous infusion of etoposide and cisplatin in metastatic breast cancer. Am J Clin Oncol 19: 125-131
25. Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194-1201
26. Sledge Jr GW (1991) Etoposide in the management of metastatic breast cancer. Cancer 67: 266-270
27. Sledge Jr GW, Roth BJ (1989) Cisplatin in the management of breast cancer. Semin Oncol 16: 110-115
28. Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger HU, Laws S, Osterwalder B (2002) Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/ advanced breast cancer pretreated with anthracyclines. Br J Cancer 86: 1367-1372
29. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L (2004) Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22: 2061-2068